Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homoharringtonine + Imatinib in CML
NCT00114959Phase 2Terminated
- Sponsor
- ChemGenex Pharmaceuticals
- Start
- Oct 2005
- Primary completion
- Jun 2008
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of homoharringtonine in chronic myeloid leukemia (CML), sponsored by ChemGenex Pharmaceuticals. Primary endpoints: Proportion of Participants With Accelerated Phase or Blast Phase CML Who Achieve a Meaningful Response at 4 months, Proportion of Participants With Chronic Phase CML Who Achieve a Meaningful Response at 4 months and 1 more. Started Oct 2005; status: terminated.
02
Drugs
homoharringtonine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00114959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114959.